apical ENaC abundance largely through signaling mechanisms that do not require Nedd4-2. This conclusion derives not only from the current paper (8), but also from work showing that aldosterone responsiveness of ENaC in the rectum is increased rather than decreased when Nedd4-2 is deleted (18) and that aldosterone still regulates ENaC trafficking in the kidney when PY motifs are deleted in vivo (4). One possibility, suggested by the current results, is that Nedd4-2-mediated ubiquitylation primarily accelerates ENaC degradation within the cell (step iii in Figure 1A ) rather than its removal from the membrane (step ii in Figure 1A ). Secondly, Nedd4-2 appears to play a physiologically significant and nonredundant role in modulating NCC abundance. That said, it should be pointed out that SGK1 also activates NCC through pathways independently of Nedd4-2 (16) and We expect that similar deep investigation into these pathogenic mechanisms, and others that will be discovered through RNA sequencing, will also reveal new therapeutic strategies. (20, 21) , resulting in enhanced expression of transcripts insensitive to microRNA regulation. This may promote tumor development and/ or progression (20, 21) . Parker and colleagues demonstrated that a miR-99a binding site in the 3′-UTR of FGFR3 was lost during fusion of FGFR3 with TACC3, causing greatly increased FGFR3 expression, an effect that was counteracted by reintroduction of the 3′-UTR of FGFR3 in the presence of miR-99a (12). Importantly, FGFR3-TACC3 fusion was demonstrated to preferentially engage ERK and STAT3 signaling and to enhance tumor progression in vivo relative to WT FGFR3, which suggests that the fusion creates a specific gain of function.
New approaches
Glioblastoma is now one of the most intensely studied of all cancers at the molecular level; however, the mapping of the mutational landscape has yet to be successfully leveraged to yield better treatment for patients. Obtaining a mechanistic understanding of this mutational landscape, particularly with regard to clarifying function of specific mutations, may go a long way toward transforming basic science knowledge into clinical benefit for patients. Here, Parker and colleagues have taken important steps toward developing a functional understanding of the consequences of the FGFR3-TACC3 fusion in glioblastoma (12). Their study, taken together with the work of Singh et al. (13), demonstrates the importance of the FGFR3-TACC3 fusion in glioblastoma, which suggests that the gain of function created by the FGFR3-TACC3 fusion is greater than the sum of its parts.
The current study also raises several questions for further investigation. First, what are the mechanisms by which the FGFR3 component of the fusion protein differentially engages downstream signaling, enabling it to more effectively activate the ERK and STAT3 signaling cascades? Second, the data from Singh et al. suggest a critical role for the TACC3 component of the fusion protein in regulating aneuploidy in a fashion dependent on FGFR3 signaling; how is that regulated? Finally, what are the therapeutic of the low grade glioma samples. Importantly, FGFR3-TACC3 fusions were mutually exclusive with EGFR, PDGFR, or MET genetic alterations, the receptor tyrosine kinase alterations commonly detected in glioblastoma. Taken together, these findings suggest an important and specific role for FGFR3-TACC3 in promoting glioblastoma growth.
This study by Parker and colleagues independently validates the very recent report by Singh et al. (13), which identified FGFR3-TACC fusions in a small subset of glioblastomas. While independent validation is essential, the real excitement of this study lies more in its identification of the novel and potentially targetable mechanism of pathogenicity created by the FGFR3-TACC3 fusion.
FGFR3 encodes a receptor tyrosine kinase that is commonly mutated in bladder and cervical cancer (14) . FGFR3 engages downstream signaling cascades that are commonly activated in cancer, including PI3K-Akt and Ras-Mek-Erk signaling (15) . In glioblastoma, a role for FGFR3 had not been previously established, although recent work suggests that it can phosphorylate PTEN to promote glioblastoma resistance to EGFR tyrosine kinase inhibitors (16) . TACC3 encodes a centrosomal protein involved in mitosis (17) that is overexpressed in lung and colon carcinomas and in multiple myeloma (18) . What are the mechanisms of its pathogenicity, and in what ways are the activities of this fusion protein greater than the sum of its parts?
Singh et al. demonstrated that the transforming capacity of FGFR3-TACC3 is related to its localization to the mitotic spindle, where it causes chromosomal missegregation and aneuploidy. Importantly, they showed that this requires FGFR kinase activity, because a pan-FGFR tyrosine kinase inhibitor abrogated the fusion protein's effects on chromosomal instability, reversing aneuploidy (13). Thus, Singh and colleagues identified one intriguing mechanism by which FGFR3-TACC3 fusion can promote tumorigenicity.
In the present study, Parker and colleagues provide an alternative and entirely new view of a mechanism driving FGFR3-TACC3 pathogenicity ( Figure  1 ). They conclude that the pathogenicity of FGFR3-TACC3 is mediated, at least in part, through loss of the miR-99a binding site. MicroRNAs typically bind the 3′-untranslated region (3′-UTR) of a tran-rier, allowing passive percutaneous transfer of antigens, which trigger skin inflammation and an allergic immune response, analogous to AD in humans (6) . This work showed that a primary skin barrier deficiency is at least one important factor in AD pathogenesis, although Th2 immunity is clearly also a major player (1) .
Making the pitch for pitch
Coal tar has been used medically since ancient times. In his epic 5-volume work, Περì ὕλης ἰατρικῆς (Latin: De Materia Medica), the Greek physician, pharmacologist, and botanist Pedanius Dioscorides (circa 40-90 CE) chronicled many and varied herbal and other remedies in use at the time, including the "grime of a gymnasium wall." While this remedy for abrasions and ulcers does not currently enjoy popularity, his suggestion of the use of bitumen or asphalt/coal tar for "inflammation" (7) has maintained traction over the succeeding 2 millennia (8). For as long as modern dermatology departments have existed, liquor picis carbonis (LPC) has been a part of their working vocabulary, and preparations containing LPC are widely considered to be effective in the treatment of psoriasis and AD. Indeed, a recent systematic review provided evidence of the efficacy of 0.5%-5% LPC preparations for both these conditions (9).
Tar, asphalt, bitumen, and pitch are related substances consisting of complex mixtures of high molecular weight organic compounds that can be derived from heat distillation of plants, wood, petrochemicals, or coal. Pitch essentially functions as a solid but is really an incredibly viscous liquid that is estimated to have more than 100 billion times the viscosity of water (10). The world's longest continuously running laboratory experiment is The University of Queensland's "Pitch Drop Experiment" (10). Begun in 1927-1930 by Thomas Parnell (it took 3 years just for the pitch to settle into a glass funnel), droplets of pitch fall under gravity only about once a decade, with the next one expected this year. We live in exciting times!
A target identified
Although the terms are somewhat ambiguous and interchangeable, pitch tends to refer to the more solid substances in this group, and tar generally refers to the more liquefied products. Coal tar is an extremely viscous liquid obtained from dry-heating coal to temperatures in the range of 900ºC to 1200°C, and is thought to consist of at least 10,000 distinct high molecular weight hydrocarbon and aromatic compounds,
